Alcon AG

ALC · SWISS

$70.17−$0.46 (−0.65%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $70.63

ALC analyst rating

HoldConsensus of 10 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy5
Hold4
Underperform1
Sell0

12-month price target · 16 analysts

Average $93.44 (+33.2% upside)

Low: $58.46
Now: $70.17
High: $124.08

Upgrades and downgrades

The latest rating actions, newest first

ALC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Oct 21, 2026	Maintains	Buy	$98.00	40%
BTIG	Oct 12, 2026	Maintains	Buy	$82.00 → $74.00	48%
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$70.00	70%
Jefferies	Sep 22, 2026	Maintains	Buy	$95.00 → $85.00	56%
Needham	Sep 15, 2026	Maintains	Buy	$98.00	40%
JP Morgan	Aug 12, 2026	Maintains	Neutral	$77.53 → $78.40	67%
Mizuho	Aug 12, 2026	Maintains	Outperform	$80.00 → $85.00	56%
Needham	Aug 11, 2026	Maintains	Buy	$95.00 → $98.00	40%
BTIG	Aug 11, 2026	Maintains	Buy	$82.00	48%
Mizuho	Jul 15, 2026	Maintains	Outperform	$85.00 → $80.00	56%

The case for and against

Updated Oct 21, 2026

Bull case

Alcon is well positioned because its pure-play leadership in ophthalmic devices combines durable franchises in contact lenses, ocular health, and surgical equipment with a broad installed base that should keep supporting recurring demand and upgrade cycles. Recent results showed ~7% xFx growth, core EPS of $0.84, and strong margin outperformance, while FY26 guidance implies $10.927B to $11.134B in sales and core operating margins of 20.7% to 21.7%, underscoring meaningful operating leverage. The outlook is further reinforced by new products like Tryptyp, Precision7, Unity, PanOptix Pro, and Vivity, which are driving share gains and should sustain mid-single digit revenue growth with double-digit EPS expansion despite softer end markets.

Bear case

Alcon is facing a negative outlook because weaker-than-expected uptake of new products and intensifying competition are limiting growth below the 6% to 8% range, while margin expansion is expected to stall in the low-20s as costs run ahead of expectations. FY26 guidance still points to net sales growth of 5% to 7% xFx and core operating margins of 20.5% to 21.5%, but a ~$100M to $150M tariff headwind, including $33M in 1Q26 expenses, will pressure COGS and blunt profitability. Even with share buybacks and some gross-margin support from a $60M tariff refund contribution in 3Q, the company’s heavy investment, competition, and rollout risks suggest shares are likely to remain range-bound.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.